Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.58 |
| ▸ | CHRNG | P07510 | 1/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | CHRND | Q07001 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10734706 | 0.85 | KDM4E (0.50) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3860137 | 0.84 | CHRNA1 (0.62) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL18527134 | 0.84 | ALDH1A1 (0.44) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL786551 | 0.84 | SMN1; SMN2 (0.51) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL6955765 | 0.82 | CES2 (0.62) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL311225 | 0.81 | HDAC8 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL9227046 | 0.81 | CHRNA1 (0.58) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL16569128 | 0.80 | CES2 (0.56) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL20702960 | 0.80 | CES2 (0.55) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL10762807 | 0.79 | CHRNA1 (0.57) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121022-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-0583271-B1 | ARYLMORPHOLINE, PREPARATION AND USE | WELLCOME FOUND (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5760224-A | ANTIDEPRESSANTS FOR TREATING PSYCHOLOGICAL DISORDERS | GLAXO WELLCOME INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5648347-A | ANTIDEPRESSANTS | GLAXO WELLCOME INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0583271-A1 | ARYLMORPHOLINE, PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992018489-A1 | ARYLMORPHOLINE, PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | CHRNA1 186/4885CHRNG 477/4885CHRNB1 168/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | CHRNA1 186/4885CHRNG 477/4885CHRNB1 168/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | CHRNA1 186/4885CHRNG 477/4885CHRNB1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.